Accumulation of DNA damage in the brain’s neurons may contribute to the development of Alzheimer’s disease. New research in FEBS Open Bio demonstrates the therapeutic potential of a drug that targets this process.

Using a mouse model of Alzheimer’s disease, investigators found that treatment with KCL-286, a molecule that activates the retinoic acid receptor-β (RARβ), enhanced the repair of DNA damage in neurons.

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

Results from the Phase 2 study were published in Blood Cancer Journal. Among 37 patients treated, 70% achieved MRD negativity, including strong responses in both Philadelphia chromosome-positive and -negative disease.

A Monash University-led study has found that an unusual pairing of two commonly used antibiotics can kill and stop the spread of resistance in a highly drug-resistant bacterium, Pseudomonas aeruginosa, which can cause life-threatening bloodstream infections, pneumonia and meningitis.

Published in The Lancet Microbe, Monash Institute of Pharmaceutical Sciences (MIPS) researchers used a validated laboratory infection system in which they were able to expose bacterial samples from infected patients to simulated antibiotic dosing regimens, as would actually occur in hospitalised patients.

Cholesterol-related heart disease remains the leading cause of death worldwide, and while doctors have more tools than ever to treat it, many patients still can't achieve safe cholesterol levels, or can't tolerate the side effects of available medications. Now, researchers from University of California San Diego School of Medicine have uncovered a hidden biological pathway that explains why high-cholesterol diets steadily chip away at our body's ability to clear harmful low-density lipoprotein (LDL) cholesterol from the blood,

Developing new medicines can require thousands of chemistry experiments to identify the right recipe for a safe, effective and ideally affordable drug.

The process is slow and labor-intensive, and many of the reactions depend on hard-to-source metals that act as essential catalysts.

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new platform that combines 3D bioprinting, advanced imaging and artificial intelligence to better monitor how cancer responds to treatment. The technology could help researchers identify promising cancer therapies more rapidly and provide a way to test treatments on a patient's own tumor cells, helping guide more personalized treatment decisions.

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections - a reality that new research from Tsinghua University may soon begin to change. Current first-line biologics targeting tumor necrosis factor (TNF) - including adalimumab (Humira), long among the world’s best-selling drugs - require injections every two weeks, potentially for decades. Prolonged use drives anti-drug antibody (ADA) formation in many patients, eroding therapeutic benefit and causing secondary treatment failure.